Author’s response to reviews

Title: Addition of nucleoside analogues to Peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to Peg-IFNα-2a: A randomized controlled trial

Authors:
yan xu (zrlxuyan@163.com)
xu wang (zrlwangxu@163.com)
zhenhua liu (sdlzh410@163.com)
Changyu Zhou (doczcy@163.com)
wenqian qi (qiwenqian_0@163.com)
jian jiao (zrljiaojian@163.com)
fan yu (yu-fan001@163.com)
honghua guo (soyguo@163.com)
ping zhao (dr.zhaoping@163.com)
Jiangbin Wang (zrlwangjb@medmail.com.cn)

Version: 3 Date: 17 Apr 2017

Author’s response to reviews:

Replies to recommendations on revision

1. We notice the removal of author Jian Jiao since original submission of the manuscript. In line with COPE guidelines, BioMed Central requires written confirmation from all authors that they agree with any proposed changes in authorship of submitted manuscripts or published articles. In such cases, we use a standardised form which we would request you and your co-authors to complete (including the removed author).

Author Jian Jiao is a member of the team at the beginning of the project. Her job is to provide the relevant data of the patients who treated with interferon, but during the course of the study, she did not provide any data. Now, communicated with all the authors, everyone think she participated in the study since the beginning, so decide not to change the authors, thank you.
2. Please amend your Trial Registration section of the abstract by including the exact registration date and name of the registry. For example: "This trial was retrospectively registered on 2015 August 13 at the China Clinical Trials Registry (ChiCTR-OCC-12002196)."

Has been modified.

3. Please amend your Availability of data statement by providing the reason why data will not be made public, and remove "[REASON WHY DATA ARE NOT PUBLIC]."

For example, you could say something similar to: "...during the current study are not publicly available in order to ensure patient confidentiality, but are available from the corresponding author on reasonable request."

Has been modified.

4. Please note the "Additional Files" section refers only to supplemental files, not figure or table files. Therefore, please rename this section "Figure Legends" and remove the table summaries from this section (table titles and captions should be provided with the tables).

For each figure, the following information should be provided:

- Figure number

- Short title of figure in sentence case (required)

- Detailed legend (optional)
For example: Figure 3. Liver smear from a 6-week-old embryo (CR length 12 mm). A remarkable cluster of macrophages is seen among primitive erythroblasts (see also Fig. 4). A granuloblast is present at the upper right. H & E. ×1,150. (Scott 1974)

Has been modified.